Comparison of the pCR Rate and DFS Among Breast Cancer Patients with Different Hormone Receptor and HER2 Statuses

作者全名："Jin, Yudi; Lan, Ailin; Dai, Yuran; Jiang, Linshan; Liu, Shengchun"

作者地址："[Jin, Yudi; Lan, Ailin; Dai, Yuran; Jiang, Linshan; Liu, Shengchun] Chongqing Med Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Chongqing 400016, Peoples R China; [Jin, Yudi] Chongqing Univ, Dept Pathol, Chongqing Key Lab Intelligent Oncol Breast Canc iC, Canc Hosp, Chongqing 400030, Peoples R China"

通信作者："Liu, SC (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Breast & Thyroid Surg, Chongqing 400016, Peoples R China."

来源：BREAST CANCER-TARGETS AND THERAPY

ESI学科分类：　

WOS号：WOS:000985394300001

JCR分区：Q2

影响因子：3.3

年份：2023

卷号：15

期号：　

开始页：327

结束页：335

文献类型：Article

关键词：HER2-low; hormone receptor; pCR; DFS

摘要："Background: Recent studies have investigated the features of breast cancer (BC) with low human epidermal growth factor receptor 2 (HER2) expression or HER2-0 expression. However, the results were inconsistent. In this study, we investigated the differences in the pathological complete response (pCR) rate and disease-free survival (DFS) between HER2-low and HER2-0 BC patients and between subgroups. Methods: HER2-negative BC patients who received neoadjuvant chemotherapy between January 2013 and December 2019 in our hospital were retrospectively reviewed. First, the pCR rate and DFS were compared between HER2-low and HER2-0 patients and among different hormone receptor (HR) and HER2 statuses. Subsequently, DFS was compared between different HER2 status populations with or without pCR. Finally, a Cox regression model was used to identify the prognostic factors. Results: Overall, 693 patients were selected: 561 were HER2-low, and 132 were HER2-0. Between the two groups, there were significant differences in N stage (P = 0.008) and HR status (P = 0.007). No significant difference in the pCR rate (12.12% vs 14.39%, P = 0.468) or DFS was observed, independent of HR status. HR+/HER2-low patients had a significantly worse pCR rate (P < 0.001) and longer DFS (P < 0.001) than HR-/HER2-low or HER2-0 patients. In addition, a longer DFS was found in HER2-low patients versus HER2-0 patients among those who did not achieve pCR. Cox regression showed that N stage and HR status were prognostic factors in the overall and HER2-low populations, while no prognostic factor was found in the HER2-0 group. Conclusion: This study suggested that HER2 status is not associated with the pCR rate or DFS. Longer DFS was found only among patients who did not achieve pCR in the HER2-low versus HER2-0 population. We speculated that the interaction of HR and HER2 might have played a crucial role in this process."

基金机构：Key Research and Development Project of Chongqing's Technology Innovation and Application Development Special Big Health Field [CSTC2021jscx-gksb-N0027]; First-class Discipline Construction Project of Clinical Medicine in the First Clinical College of Chongqing Medical University [472020320220007]

基金资助正文："Funding This work was supported by the Key Research and Development Project of Chongqing's Technology Innovation and Application Development Special Big Health Field (Grant no. CSTC2021jscx-gksb-N0027) , and the First-class Discipline Construction Project of Clinical Medicine in the First Clinical College of Chongqing Medical University (Grant no. 472020320220007) ."